Teva Pharmaceutical Industries today
Teva Pharmaceutical Industries
- 52-week range
- $ 11.83
▼
$ 22.80
- Value is valuable
- $ 22.00
Teva Pharmaceuticals Industries Ltd NYSE: Teva It is the world’s largest producer of generics, with more than 500 common and bi -like methods of treatment in a wide portfolio. The giant of the medical sector also has a line of proprietary drugs that contribute to growth.
Its special drugs consider specific conditions, including respiratory diseases, oncology and disorders of the central nervous system (CNS). His shares took 17% of the fall during the days after the release of arrival in the fourth quarter of 2024. The cautious leadership of Teva in 2025 did not reach the consensus assessment. With shares trading only 6.8 -profit, Value investors can consider this as an opportunity to buy.
Transformation year of 2024
Teva Pharmaceuticals, like many other large manufacturers of drugs and pharmacies, such as Johnson and Johnson NYSE: JNJIN Allergan PLC NYSE: AGNIN CVS Health Co. NYSE: CVSAnd Walgreens Boots Alliance Inc. NASDAQ: WBAThey were involved in settlements for their participation in the opioid epidemic. The black cloud Teva surrounding opioid settlement was scattered after 2023, when the company agreed to make current payments and provide its common version of Narcan as part of the agreement. This notes 2024 as a year of normalization and return to growth.
Teva CEO Richard Francis commented: “2024 marked the transforming year for Teva, which led to the second year of growth due to our common products and key innovative products. Having focused on the strict implementation of our strategy for giving up growth throughout the year, we continued to reach important stages in each of its four pillars, including exceed the prospects of our key innovative products, the development of our generics business in all segments and accelerating our early -The-innovative pipeline, including the positive results of the 2B phase for our asset Duvakitug (Anti-TL1A). These results lay the way for key tests in the disease of the Crohn and ulcerative colitis, as well as potentially, other immunological and fibrous indications outside, in cooperation with our partner, sanofi. ”
Concluding 2024 with a strong finish for a strong year
Teva Q4 2024 results were relatively strong. The company published EP 71 centers, which corresponded to consensus estimates.
Revenue decreased by 5.1% compared to the same period last year (year) to 4.23 billion dollars. USA, surpassing 4.23 billion dollars. USA.
Throughout 2024, revenue increased by 6% to $ 16.5 billion. In the United States, its business was 15% growth, 6% in Europe and 15% in international markets. Global brand drug sales were reliable.
Austedo exceeded income of $ 1.6 billion. The USA, surpassing the company’s prospects for 2024.
Ajoy revenues grew by 17% to 507 million dollars. Uzedy’s income exceeded prospects for $ 100 million, bringing $ 117 million in 2024.
The leadership was on the cautious side
Teva released its preliminary guidance of 2025 on EPS in the amount of $ 2.65 to $ 2.65 compared to consensus estimates of $ 2.78. It is expected that the revenue for the whole year will be from 16.8 to $ 17.4 billion. USA against 17.09 billion dollars. USA. This is what caused the sale of shares.
The first market is the general medicine GLP-1 in 2025
In January 2025, Teva entered into an agreement on a license and supply for the proposed treatment of GLP-1 in the United States and Europe. The company with the first in the market with the launch of the common version of Sandostanin Lar Depot and Liraglutide Inuction 1.8 mg. This is an authorized generic from Victoza.
Liglutide is an agonist GLP-1, which is an active ingredient in Victoza. Victoza is more old GLP-1 drug, made Novo Nordisk a/s. NYSE: NVOManufacturer Semaglutida, active ingredient in the OREMICA and VEGOVA. Victoza was an early GLP-1, which was used specifically for type 2 diabetes, and patients lost an average of 6.2 pounds. This has laid the way for the development of new GLP-1 drugs, and then for weight loss.
Teva Stock forms a symmetrical rupture of the triangle
The symmetrical triangle consists of the descending (falling) resistance of the line of the upper line of the trend converging from the ascending (ascending) reference line of the lower trend at the top of the top. The breakthrough occurs when the shares rise above the resistance of the upper line of the trend line. The breakdown occurs when the action collapses below the lower support of the trend line. The breakthrough or rupture becomes outstanding, since the action approaches the point of the top when the channel is narrowed.
Teva has formed a symmetrical triangle with the upper trend line formed in a height of $ 22.80, and the rise of lower trend support, formed when filling in a gap of $ 19.03. Teva cut to the side of the top before releasing the release of income to the level of $ 19.75, and, entering FIB below at $ 17.26. Fibonacci (FIB) The pumping support levels are $ 17.26, $ 16.83, $ 16.25, US dollars and $ 15.81.
The average consensus price of Teva shares is 23.56% higher – $ 22.00, and the highest target price of analysts is $ 30.00. He has six ratings of buying six analysts and 2 ratings. Promotions have 1.39% short percentage.
Bull investors can consider the possibility of using cash, at the levels of FIB rollback to buy DIP. In the case of the appointment of shares, the writing of covered calls at the levels of increasing FIB performs a wheel strategy for income.
Before considering Teva Pharmaceutical Industries, you will want to hear this.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market conquers … And Teva Pharmaceutical Industries was not on the list.
While Teva Pharmaceutical Industries currently has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
As the AI market heats up, investors who have a vision of artificial intelligence can see real profit. Learn about the industry as a whole, as well as about seven companies that perform work with AI.
Get this free report